Deedwania Prakash, Stone Peter H, Bairey Merz C Noel, Cosin-Aguilar Juan, Koylan Nevres, Luo Don, Ouyang Pamela, Piotrowicz Ryszard, Schenck-Gustafsson Karin, Sellier Philippe, Stein James H, Thompson Peter L, Tzivoni Dan
UCSF School of Medicine, San Francisco, Calif, USA.
Circulation. 2007 Feb 13;115(6):700-7. doi: 10.1161/CIRCULATIONAHA.106.654756. Epub 2007 Feb 5.
Clinical trials have demonstrated that, compared with placebo, intensive statin therapy reduces ischemia in patients with acute coronary syndromes and in patients with stable coronary artery disease. However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes.
A total of 893 ambulatory coronary artery disease patients (30% women) 65 to 85 years of age with > or = 1 episode of myocardial ischemia that lasted > or = 3 minutes during 48-hour ambulatory ECG at screening were randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d and followed up for 12 months. The primary efficacy parameter (absolute change from baseline in total duration of ischemia at month 12) was significantly reduced in both groups at month 3 and month 12 (both P<0.001 for each treatment group) with no significant difference between the treatment groups. Atorvastatin-treated patients experienced greater low-density lipoprotein cholesterol reductions than did pravastatin-treated patients, a trend toward fewer major acute cardiovascular events (hazard ratio, 0.71; 95% confidence interval, 0.46, 1.09; P=0.114), and a significantly greater reduction in all-cause death (hazard ratio, 0.33; 95% confidence interval, 0.13, 0.83; P=0.014).
Compared with moderate pravastatin therapy, intensive atorvastatin therapy was associated with reductions in cholesterol, major acute cardiovascular events, and death in addition to the reductions in ischemia observed with both therapies. The contrast between the therapies' differing efficacy for major acute cardiovascular events and death and their nonsignificant difference in efficacy for reduction of ischemia suggests that low-density lipoprotein cholesterol-lowering thresholds for ischemia and major acute cardiovascular events may differ. The Study Assessing Goals in the Elderly (SAGE) demonstrates that older men and women with coronary artery disease benefit from intensive statin therapy.
临床试验表明,与安慰剂相比,强化他汀类药物治疗可减少急性冠状动脉综合征患者和稳定型冠状动脉疾病患者的缺血情况。然而,迄今为止尚无研究评估在老年稳定型冠状动脉综合征患者中强化他汀治疗与中等强度他汀治疗的效果。
共有893例年龄在65至85岁的门诊冠状动脉疾病患者(30%为女性),在筛查时48小时动态心电图显示有≥1次持续≥3分钟的心肌缺血发作,将其随机分为阿托伐他汀80mg/天组或普伐他汀40mg/天组,并随访12个月。在第3个月和第12个月时,两组的主要疗效参数(第12个月时缺血总时长相对于基线的绝对变化)均显著降低(各治疗组P均<0.001),治疗组之间无显著差异。阿托伐他汀治疗的患者低密度脂蛋白胆固醇降低幅度大于普伐他汀治疗的患者,主要急性心血管事件有减少趋势(风险比,0.71;95%置信区间,0.46,1.09;P = 0.114),全因死亡显著降低(风险比,0.33;95%置信区间,0.13,0.83;P = 0.014)。
与中等强度的普伐他汀治疗相比,强化阿托伐他汀治疗除了能像两种治疗一样减少缺血外,还能降低胆固醇、主要急性心血管事件和死亡风险。两种治疗在主要急性心血管事件和死亡方面的疗效差异与在减少缺血方面的疗效无显著差异形成对比,这表明缺血和主要急性心血管事件的低密度脂蛋白胆固醇降低阈值可能不同。老年人目标评估研究(SAGE)表明,患有冠状动脉疾病的老年男性和女性可从强化他汀治疗中获益。